The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Constraints and challenges in access to insulin: a global perspective
Open accessAbstract
Substantial attention has been given to the issue of access to medicines for communicable diseases; however, access to essential medicines for diabetes, especially insulin, has had insufficient focus. Although insulin was discovered in 1921, the drug is unattainable to many globally, and this Review aims to highlight the range and complexity of factors that contribute to this unattainability. Manufacturers' selling prices of various insulin formulations and presentations, duties, taxes, mark-ups, and other supply chain costs affect the price of insulin and hence the drug's affordability to health systems and individuals. Unlike drugs for HIV and AIDS, the production of generic or biosimilar insulin has not had an effect on the overall market. Other factors contributing to poor availability of insulin include its quantification at the national level, in-country distribution, and determination of needs at lower levels of the health system. Although insulin is essential for the survival of people with type 1 diabetes and is needed for improved management of diabetes for some people with type 2 diabetes, very little has been done globally to address the issue of access, despite the UN's political commitment to address non-communicable diseases and ensure universal access to drugs for these disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Improvements in the Life Expectancy of Type 1 Diabetes
Miller, R. G., Secrest, A. M., Sharma, R. K., Songer, T. J., & Orchard, T. J. (2012) · Diabetes · doi:10.2337/db11-1625 · Cited by 293
Why is there no generic insulin? Historical origins of a modern problem
Greene, J. A., & Riggs, K. R. (2015) · New England Journal of Medicine · doi:10.1056/nejmms1411398 · Cited by 81
Cited by
Gregory, G. A., Robinson, T. I. G., Linklater, S. E., Wang, F., Colagiuri, S., de Beaufort, C., Donaghue, K. C., Harding, J. L., Wander, P. L., Zhang, X., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00218-2 · Cited by 1,149
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives
Chan, J. C. N., Lim, L.-L., Wareham, N. J., Shaw, J. E., Orchard, T. J., Zhang, P., Lau, E. S. H., Eliasson, B., Kong, A. P. S., Ezzati, M., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32374-6 · Cited by 793
Essential medicines for universal health coverage
Wirtz, V. J., Hogerzeil, H. V., Gray, A. L., Bigdeli, M., de Joncheere, C. P., Ewen, M. A., Gyansa-Lutterodt, M., Jing, S., Luiza, V. L., Mbindyo, R. M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31599-9 · Cited by 661
Self-citationPatterson, C. C., Karuranga, S., Salpea, P., Saeedi, P., Dahlquist, G., Soltesz, G., & Ogle, G. D. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107842 · Cited by 560
Insulin Access and Affordability Working Group: Conclusions and Recommendations
Cefalu, W. T., Dawes, D. E., Gavlak, G., Goldman, D., Herman, W. H., Van Nuys, K., Powers, A. C., Taylor, S. I., Yatvin, A. L., & on behalf of the Insulin Access and Affordability Working Group (2018) · Diabetes Care · doi:10.2337/dci18-0019 · Cited by 256
Metadata
- Authors
- Beran, D., Ewen, M., & Laing, R.
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2016-03
- Volume
- 4
- Issue
- 3
- Pages
- 275-285
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2266663730
- Cited by
- 186
- References
- 3
- FWCI
- 40.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Constraints and challenges in access to insulin: a global perspective. https://app.cochat.ai/papers/10.1016/s2213-8587(15)00521-5
- The paper
- Beran, D., Ewen, M., & Laing, R. (2016). Constraints and challenges in access to insulin: a global perspective. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(15)00521-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
